Navigation Links
Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naive and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:11/2/2013

WASHINGTON, Nov. 2, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced the presentation of new data at The Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, DC for the investigational protease inhibitor simeprevir (TMC435) in the treatment of genotype 1 chronic hepatitis C in treatment-naive and treatment-experienced adult patients with compensated liver disease. In analyses of the Phase 3 QUEST-1 and QUEST-2 studies in treatment-naive patients and the Phase 3 PROMISE study in prior relapse patients, the efficacy of simeprevir was observed in hepatitis C patients, including patients with the IL28B TT genotype and METAVIR scores of F4.

"Patients with certain baseline characteristics can be more likely to fail or relapse after prior treatment," said Ira Jacobson, M.D., simeprevir clinical trial investigator, chief of the Division of Gastroenterology and Hepatology, Vincent Astor Distinguished Professor of Medicine, Weill Cornell Medical College, and attending physician, New York-Presbyterian Hospital/Weill Cornell Medical Center. "The breadth of simeprevir data presented at AASLD reinforce its potential as a treatment option for patients and will offer important guidance to physicians once simeprevir is approved."   

On October 24, the U.S. Antiviral Drugs Advisory Committee of the FDA voted unanimously (19-0) to recommend approval of the new drug application filed by Janssen Research & Development, LLC for simeprevir administered once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C virus (HCV) in adult patients with compensated liver disease.

Pooled Analysis from QUEST-1 and QUEST-2 Confirms Clinical Benefit of Simeprevir in Sub-Populations of Patients (Abstract 1122)        
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
3. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
4. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
5. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
6. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
9. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
10. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
11. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  Semler Scientific, ... emerging medical risk assessment company that develops patented ... and evaluating chronic diseases, today reported financial results ... June 30, 2014. "The second ... Semler," said Doug Murphy-Chutorian , M.D., chief ...
(Date:7/25/2014)... SAN DIEGO , July 25, 2014  Arena ... it will provide a corporate update and report second ... Market opens on Friday, August 1, 2014. That same ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). ... by dialing 877.643.7155 for domestic callers and 914.495.8552 for ...
(Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals ... compounds that will be added to Parnell,s already ... CIMTECH Pty Ltd, a biotechnology company. The compounds ... have shown promise in bone regeneration and dermal ... develop the compounds for the veterinary market with ...
Breaking Medicine Technology:Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4
(Date:7/27/2014)... 27, 2014 The European Bromine market report ... and forecast of revenue. , Bromine market in European region ... and UK. Germany and France that forms a dominant share ... derivatives in Europe. , Browse through the TOC of ... the in-depth analysis provided Browse through the TOC of the ...
(Date:7/27/2014)... Australia (PRWEB) July 27, 2014 ... in Australia is restricted to two companies, heavy ... to IBISWorld industry analyst Spencer Little, “Demand for ... due to rising health concerns, frequent anti-smoking campaigns, ... result, industry revenue is estimated to fall at ...
(Date:7/27/2014)... 2014 iFitDress.com, a well-known wedding dress ... of wedding gowns with sleeves . Furthermore, it ... they are now available with big discounts, from 20 ... that iFitDress.com is one of the big players in ... the new wedding gowns feature fine craftsmanship and charming ...
(Date:7/27/2014)... Alta Resources , a global provider of ... brands, announced today that it plans to fill more ... Florida and the Philippines. , A majority of the ... seasonal ramp-ups that require additional staffing in preparation for ... 2015. As more consumers become eligible for health-plan coverage ...
(Date:7/27/2014)... Individuals that have been involved in an ... the newly released ebook guide for how to ... help those struggling through the aftermath of personal injury due ... guide attempts to help individuals understand the legal process and ... of their doctors and an experienced attorney. , Contact ...
Breaking Medicine News(10 mins):Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Discounted Wedding Gowns With Sleeves Offered At iFitDress.com 2Health News:Alta Resources to Fill Approximately 2,500 Positions 2Health News:Alta Resources to Fill Approximately 2,500 Positions 3Health News:Auto Accident Personal Injury Ebook Guide Released by The Jones Firm 2
... In some cases, an apple a day may keep the ... may also do the job. A new study by ... the use of Aspirin as a preventative measure for cardiovascular ... collected data from clinical trials that looked at whether taking ...
... 5 (HealthDay News) -- Small rural hospitals in the United ... patient outcomes than larger hospitals, a new study finds. ... beneficiaries in order to assess the care provided by critical ... care beds and are located more than 35 miles from ...
... ROCHESTER, Minn. For nearly two decades, the medical ... lightning-rod topic of stem cells, in particular the controversy ... years ago successfully "reprogrammed" adult body cells to become ... over. Those redirected cells, known as induced pluripotent cells, ...
... HealthDay Reporter , TUESDAY, July 5 (HealthDay News) ... for easing low back pain in the short term, a ... mostly middle-aged, female and white, all of whom had chronic ... of either relaxation massage or structural massage were better able ...
... More breast cancer patients than previously believed may ... of Michigan Comprehensive Cancer Center study shows. Researchers ... whether cancer patients receive appropriate care and found that ... cancer patients undergo radiation treatments. The Surveillance ...
... Society invites you to attend the 2012 Symposium on ... held March 12-14, 2012, at the Marriott Baltimore Waterfront ... exciting first-time event. The symposium aims to bring ... and practice realms of the health-care community and to ...
Cached Medicine News:Health News:Higher daily dose of aspirin could play key role in preventing heart attacks for those with diabetes 2Health News:Small, Rural Hospitals Provide a Lower Quality of Care: Study 2Health News:Moving beyond embryonic stem cells: Encouragement on the horizon 2Health News:Massage Beats Meds for Lower Back Pain, Study Says 2Health News:Radiation rates for breast cancer may be underestimated, U-M study finds 2Health News:HFES sponsors 2012 Symposium on Human Factors and Ergonomics in Health Care 2
... detection and semi-quantitation of ... antigen in serum as ... diagnosis of autoimmune disease. ... performed either manually or ...
... for the detection and quantitation ... nuclear antigens (ENA) [RNP, Sm, ... in human serum. SS-A (Ro) ... in the diagnosis of SLE, ...
... Enzyme-linked immunosorbent assays for ... IgG antibodies to extractable nuclear ... human serum. SS-A (Ro) and ... the diagnosis of SLE, subacute ...
... Inc. ENA Screen ELISA test system is ... antibodies to extractable nuclear antigens (anti-ENA) in ... directional insert, this test system is capable ... such as those against Jo-1, Sm, Sm/RNP, ...
Medicine Products: